Impel Pharmaceuticals Investor Relations Material
Latest events
Q1 2023
Impel Pharmaceuticals
Q3 2023
14 Nov, 2023
Q2 2023
18 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Impel Pharmaceuticals Inc
Access all reports
Impel Pharmaceuticals Inc is a biopharmaceutical company that develops intranasal drug delivery treatments for central nervous system disorders. The company’s delivery platform enables rapid and targeted administration of therapeutics for conditions such as migraines and Parkinson’s disease. It focuses on commercializing treatments through healthcare provider networks. Impel Pharmaceuticals Inc is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
IMPL
Country
🇺🇸 United States